Spain · Delayed Price · Currency is EUR Pharma Mar Earnings Call Transcripts
Fiscal Year 2026
-
Germany and Austria launches of lurbinectedin–atezolizumab were described as ahead of expectations, with broader European reimbursement expected within a year. Focus also turned to tarlatamab sequencing, LAGOON’s failed endpoint and a H1 2027 SaLuDo readout.
-
Recurring revenues grew strongly in H1 2026, driven by Zepzelca's U.S. royalties and early European launch, offsetting prior year non-recurring items. Cash flow and net cash improved, with rapid EU market access and further revenue growth expected in H2.
Fiscal Year 2025
-
2025 saw 27% revenue growth, a fivefold EBITDA increase, and major milestones for Zepzelca, including U.S. first-line approval. Strong cash flow and pipeline progress position the company for further growth in 2026.
-
Revenues grew 18% year-over-year, driven by strong oncology sales and major licensing deals. EBITDA reached EUR 25 million, net profit EUR 19.4 million, and ZEPZELCA saw significant progress in Europe, China, and regulatory filings.
-
IMforte data for lurbinectedin maintenance in small cell lung cancer are seen as practice-changing, offering meaningful survival benefits and manageable toxicity. Rapid adoption is expected in Europe, though future competition from tarlatamab may impact its long-term role.
Fiscal Year 2024
-
Double-digit revenue growth in 2024 was driven by Sapselca and Yondelis, with EBITDA rising to EUR 13 million and net profit to EUR 26.2 million. Positive clinical milestones and strong cash position support future growth, with regulatory submissions and new launches expected in 2025.
-
H1 2024 saw revenue growth driven by Zepzelca and increased royalties, with strong R&D investment and a robust balance sheet. Key clinical trials are progressing well, and Zepzelca's China approval is anticipated soon, while share buybacks and dividends continue.